医学
乳腺癌
表阿霉素
肿瘤科
内科学
卡铂
杂合子丢失
激素受体
癌症
化疗
紫杉醇
队列
新辅助治疗
乳房切除术
生物标志物
外科肿瘤学
激素
前瞻性队列研究
激素疗法
激素疗法
吉西他滨
乳腺
随访中值
作者
Arne V. Pladsen,Marianne Lislerud Smebye,Øystein Garred,Elin Borgen,Eivind Valen Egeland,Mads Haugland Haugen,Maria Aanesland Dahle,Lina Prasmickaite,Gunhild Mari Mælandsmo,Eivind J. Hovig,Sigve Nakken,Alexandra Østgaard,Inger Riise Bergheim,Kristin Valborg Reinertsen,Hege Oma Ohnstad,Ellen Schlichting,Helle Kristine Skjerven,Anne‐Lise Børresen‐Dale,Erik Wist,Bjørn Naume
标识
DOI:10.1158/1078-0432.ccr-26-2212
摘要
PURPOSE: This prospective, randomized neoadjuvant study evaluated DNA-based biomarkers to identify breast cancer patients most likely to benefit from carboplatin (Cb). While Cb improves outcomes in triple-negative breast cancer (TNBC), responses vary, and its role in aggressive hormone receptor-positive breast cancer (HR+BC) remains uncertain. PATIENTS AND METHODS: Patients (N = 187) with early, high-risk, HER2-negative cT2-4 tumors received 12 weekly paclitaxel with or without Cb, followed by four cycles of epirubicin and cyclophosphamide. Pretreatment tumor whole-exome sequencing was used to calculate the complex arm-wise aberration index (CAAI), loss of heterozygosity (LOH) fraction, and homologous recombination deficiency (HRD) status. RESULTS: For TNBC patients, pathologic complete response (pCR) was obtained in 69% (24/35) with Cb versus 43% (16/37) with control (p = 0.036) whereas 74% (26/35) and 65% (24/37), respectively, acquired either pCR or recidual cancer burden class 1 (RCB 1; p = 0.45). Cb significantly prolonged event-free survival (EFS; p = 0.017). In patients with a low genomic LOH fraction, Cb improved EFS (p = 0.007). Low genomic LOH fraction also indicated an unfavourable prognosis without Cb, confirmed in an independent cohort (n = 67, p = 0.02). For HR+BC patients, pCR was 15% (9/60) with Cb versus 11% (6/55) with control (p = 0.59), but the proportion achieving low residual cancer burden (pCR and RCB 1) increased from 16% (9/55) to 35% (21/60; p = 0.033). Among patients having HR+BC tumors with HRD, 5 of 8 attained pCR with Cb compared with 4 of 47 HRD-negative tumors (p = 0.002). CONCLUSION: This study indicates distinct predictive values of complex DNA-based biomarker analyses for breast-cancer subtypes. Low genomic LOH fraction may identify TNBC patients who benefit most from Cb, while HRD may guide Cb use in HR+BC.
科研通智能强力驱动
Strongly Powered by AbleSci AI